{
    "nct_id": "NCT06516965",
    "official_title": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis",
    "inclusion_criteria": "* Male and female participants 18 to 75 years of age.\n* Clinical diagnosis of PN for at least 3 months prior to Screening visit.\n* Pruritus, defined as an average Itch NRS score ≥ 7 during the 7 days prior to Day 1/Baseline.\n* Total of ≥ 20 pruriginous lesions on ≥ 2 different body regions (both legs, and/or both arms, and/or trunk) at Screening and Day 1/Baseline.\n* Documented history of treatment failure, demonstrated intolerance, or contraindication to a previous PN treatment.\n* Willingness to avoid pregnancy or fathering children.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Chronic pruritus due to a condition other than PN or neuropathic and psychogenic pruritus.\n* Diagnosis of PN secondary to medications.\n* Active AD lesions (signs and symptoms other than dry skin) within 3 months prior to Screening visit.\n* Women who are pregnant (or are considering pregnancy) or breastfeeding.\n* Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.\n* Evidence of infection with TB, HBV, HCV or HIV.\n* History of failure to any topical or systemic JAK or TYK2 inhibitor as treatment of PN or any inflammatory disease.\n* Laboratory values outside of the protocol-defined ranges.\n\nOther protocol-defined Inclusion/Exclusion Criteria apply.",
    "miscellaneous_criteria": ""
}